ponatinib,blinatumomab
otsuka,takeda,incyte,astellas,amgen
[' aca ', 'leusm', 'ponatinib', 'ph+ all', 'leukemia']
#ash22 #leusm short: 2yr efs 92%, os 95% (all but 1 wo allohct). 5% gr1-2 crs, 2 arterial occlusive events, few gr3+ aes. impressive results that truly revolutionize the mgmt of ph+ all! nice work and leukemia group! 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)